Journal of Ayurveda and Integrated Medical Sciences

2025 Volume 10 Number 5 MAY
Publisherwww.maharshicharaka.in

A Comparative Clinical Study to Evaluate the Efficacy of Madhukadi Ghrita and Samangadi Leha in enhancing Vyadhikshamatva w.s.r. to Immunity in Children

Dharwal R1*, Singh K2, Sharma R3
DOI:10.21760/jaims.10.5.3

1* Rohini Dharwal, Assistant Professor, Department of Kaumarbhritya, Abhilashi Ayurvedic Medical College and Research Institute, Chail-Chowk, Mandi, Himachal Pradesh, India.

2 Karam Singh, Lecturer, PG Department of Kaumarbhritya, Rajiv Gandhi Government Post Graduate Ayurvedic College and Hospital, Paprola, Himachal Pradesh, India.

3 Rakesh Sharma, Head, PG Department of Kaumarbhritya, Rajiv Gandhi Government Post Graduate Ayurvedic College and Hospital, Paprola, Himachal Pradesh, India.

Background: Despite tremendous progress in recent decades, infectious diseases remain a leading cause of morbidity and mortality in pediatric population worldwide. Optimal immune health directly depends upon Hitakara Aahar and Vihar. Maintaining a diet and lifestyle aligned with one’s Satmya help strengthening the defense mechanism of the body. Equilibrium of Doshas, Bala and Ojas capable of effectively combating disease. Strengthening the immune system in a natural way there are many formulations like Rasayana, Balya and Ojovridhikara drugs.

Aims and Objective: To evaluate, compare the efficacy and clinical safety of Madhukadi Ghrita and Samangadi Leha in children.

Materials and Methods: A randomized, comparative clinical trial was conducted on 40 pediatric patients belonging to age group 2-10 years for 4 weeks who were suffering from recurrent RTI and GIT infections. The patients were divided into two groups: Group I received Madhukadi Ghrita, while Group II was treated with Samangadi Leha. The clinical efficacy of both interventions was assessed based on subjective and objective criteria, symptomatic relief and overall improvement.

Results: Both groups significantly improved clinical symptoms. Madhukadi Ghrita is preferable for immediate symptom alleviation, whereas Samangadi Leha is beneficial for long-term immune system support.

Conclusion: This study seeks to provide safe and effective Ayurvedic alternatives for enhancing Vyadhikshamatva (immunity) in children, fostering long-term immune resilience and overall well-being.

Keywords: Vyadhikshamatva, Balya, Immunity, Madhukadi Ghrita, Samangadi Leha

Corresponding Author How to Cite this Article To Browse
Rohini Dharwal, Assistant Professor, Department of Kaumarbhritya, Abhilashi Ayurvedic Medical College and Research Institute, Chail-Chowk, Mandi, Himachal Pradesh, India.
Email:
Dharwal R, Singh K, Sharma R, A Comparative Clinical Study to Evaluate the Efficacy of Madhukadi Ghrita and Samangadi Leha in enhancing Vyadhikshamatva w.s.r. to Immunity in Children. J Ayu Int Med Sci. 2025;10(5):11-19.
Available From
https://jaims.in/jaims/article/view/4321/

Manuscript Received Review Round 1 Review Round 2 Review Round 3 Accepted
2025-04-06 2025-04-26 2025-05-06 2025-05-16 2025-05-26
Conflict of Interest Funding Ethical Approval Plagiarism X-checker Note
None Nil Yes 12.63

© 2025 by Dharwal R, Singh K, Sharma R and Published by Maharshi Charaka Ayurveda Organization. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License https://creativecommons.org/licenses/by/4.0/ unported [CC BY 4.0].

Download PDFBack To ArticleIntroductionAim and ObjectivesMaterials and MethodsResultsDiscussionConclusionReferences

Introduction

Globally, infectious diseases, including pneumonia, diarrhoea and malaria, remain a leading cause of under-five deaths, along with preterm birth and intra-partum related complications.[1]

Frequent, prolonged, or severe infections indicate immunodeficiency. Recurrent respiratory and gastrointestinal infections are common in children, ranging from mild to severe conditions. Factors like an immature immune system, environmental exposures, and nutritional deficiencies contribute to their high prevalence.

Immunity refers to the body’s ability to resist or defend against harmful foreign substances such as bacteria, viruses and other pathogenic agents. The inherent defence mechanisms that are present in an individual even before first exposure to pathogen are known as innate or natural immunity.[2]

The concept of strong immune system is thought to be a result of well functioning bodily systems and the presence of balanced state of three Doshas (Vata, Pitta and Kapha). The key principles of immunity include Aahar, Lehana, Dinacharya, Ritucharya, Yogasana, Pranayam and Medhya Rasayana. Maintaining a diet and lifestyle aligned with one’s Satmya help strengthen the natural defense mechanism of the body. This alignment ensures that the body is well nourished, balanced and capable of effectively combating disease.[3]

Immunomodulatory drugs are classified into categories such as Rasayana, Balya and Ojovridhikara.[4]

Many plant-based compounds with potential immunotherapeutic effects have been discovered, validating their use in traditional medicine and paving the way for future research. The ingredients of these selected formulations form a distinctive blend possessing Balya (strengthening), Medhya (intellect-enhancing) and Rasayana (rejuvenating) properties.[5]

Considering the aforementioned factors and aiming to relieve children from restlessness, exasperation and discomfort, a dedicated effort has been made in the present study titled “A Comparative Clinical Study to Evaluate the Efficacy of Madhukadi Ghrita and Samangadi Leha in enhancing Vyadhikshamatva w.s.r. to Immunity in Children.”

Aim and Objectives

1. To study the efficacy of Madhukadi Ghrita and Samangadi Leha on Vyadhikshamatva in children.
2. To compare the efficacy of Madhukadi Ghrita and Samangadi Leha.
3. To evaluate the clinical safety of Madhukadi Ghrita and Samangadi Leha in children.

Materials and Methods

Total 40 patients were registered from the Kaumarbhritya-Balroga OPD/IPD, RGGPG Ayurvedic College and Hospital, Paprola, randomly fulfilling the criteria of this study.

A case proforma was filled with the data obtained by interrogation, physical examination and collection of details of each child.

Inclusion Criteria

1. Patient between 2 to 10 years of Age.
2. Patient suffering from recurrent GIT and RTIs.
3. Patient /Parents willing to participate in the trial.

Exclusion Criteria

1. Patient below 2 years of age and above 10 years.
2. Patients with congenital, hereditary or acute systemic illness (Jaundice, Hypothyroidism, Renal impairments and Electrolyte imbalance).
3. Patient with physical disability.

Grouping of Patients

In the present research work, a total of 40 patients were registered and studied under two groups.

Group-I

20 patients in this group were managed with Madhukadi Ghrita.

  • Route of Administration: Oral
  • Dosage: 5ml/kg/day in two divided doses.
  • Anupana: Lukewarm Milk.

Group-II

In this group 20 patients were given the trial drug Samangadi Leha.

  • Route of Administration: Oral
  • Dosage: 500mg/kg/day in two divided doses.
  • Anupana: Lukewarm Milk.

Duration of the trial: 4 weeks

Follow-up: 2nd, 4th week and subsequent follow ups on 8th, 12th week

Criteria of Assessment of Results

The assessment of the effect of trial drugs was done based on the subjective and objective criteria. All the patients were examined before initiation and after completion of the trial.

The improvement was assessed based on relief in severity of symptoms and changes in laboratory investigations were also taken into consideration.

Subjective Criteria

All the sign & symptoms depending upon their severity and frequency were graded on 4-point scale i.e., 0,1,2,3. The clinical improvement during and after trial were correlated with the previous grading of sign and symptoms.

Table 1: Grading of sign and symptoms.

IllnessGrade
TemperatureSeverity
Nil0
Slight fever and /or some aches1
Definite elevation of temperature, moderate aches, headache2
Severely incapacitated by general symptoms3
Frequency
Nil0
1 episode in last 3 months1
2 episodes in last 3 months2
>=3 episodes in last 3 months3
Running NoseSeverity
Nil0
Mild discharge, stuffiness, sneezing1
Heavy, clear discharge and /or stuffiness2
Yellow or green nasal discharge3
Frequency
Nil0
1 episode in last 3 months1
2 episodes in last 3 months2
>=3 episodes in last 3 months3
CoughSeverity
No cough0
Mild, isolated cough, without additional symptoms1
Moderate, paroxysmal cough, without additional symptoms2
Severe, strenuous cough, accompanied by chest discomfort3
Frequency
Nil0
1 episode in last 3 months1
2 episodes in last 3 months2
>=3 episodes in last 3 months3
Sore ThroatSeverity
Normal0
Throat discomfort1
Pain in throat with difficulty in swallowing of food2
Pain in throat and difficulty in swallowing even saliva3
Frequency
Nil0
1 episode in last 3 months1
2 episodes in last 3 months2
>=3 episodes in last 3 months3

TonsilsSeverity
Normal0
Enlarged without inflammation1
Enlarged with inflammation2
Yellowish spot on tonsils3
Frequency
Nil0
1 episode in last 3 months1
2 episodes in last 3 months2
>=3 episodes in last 3 months3
Pain AbdomenSeverity
No pain0
Mild pain (Nagging, annoying, interfering little with ADLs)1
Moderate pain (interferes significantly with ADLs)2
Severe pain (Disabling, Unable to perform ADLs)3
Frequency
Nil0
1 episode in last 3 months1
2 episodes in last 3 months2
3 episodes in last 3 months3
VomitingSeverity
Nil0
Forceful ejection of small amount of gastric contents (Milk/Food)1
Projectile Vomiting (Large amount of gastric content)2
Bilious Vomiting (containing large amount of bile)3
Frequency
Not any episode0
1-2 episodes in last 3 months1
3-5 episodes in last 3 months2
4-6 or more episodes in last 3 months3
Loose StoolsSeverity
Nil0
2-3 stools above normal per day1
4-6 stools above normal per day2
>=7 stools above normal per day3
Frequency
Nil0
1 episode in last 3 months1
2episodes in last 3 months2
3episodes in last 3 months3

Objective Criteria

  • Serum IgG

Laboratory investigations

  • CBC (Hb gm%, TLC, DLC)
  • ESR
  • LFT (SGOT, SGPT)

Statistical Analysis

Data was statistically analyzed by using appropriate tests “Student’s paired ‘t’ test” for individual group and “Unpaired ‘t’ test” for intergroup comparison were used for parametric data.

For non-parametric data “Wilcoxon Signed Rank Sum test” was used for ind. group & “Mann Whitney ‘U’ test” was used for intergroup comparison.

The obtained results were interpreted as follows:

  • Highly significant p<0.001
  • Significant p<0.05
  • Insignificant p>0.05

Assessment of Results

Marked improvement75% - 100% relief
Moderate improvement51% - 74% relief
Mild improvement25% - 50% relief
No improvement<25% relief

Results were assessed based on the overall effect of the trial drugs on subjective as well as objective parameters and categorized as;

Results

Table 2: Therapy effect on subjective parameters depending upon their severity (before and after treatment)

Signs and symptomsGroupsMeand% ReliefSD±SE±W valuep value
BTAT
FeverGroup I10.20.880%0.6960.156-91<0.001
Group II0.80.10.787.5%0.8010.179-550.002
Running NoseGroup I0.350.10.2571.42%0.5500.123-100.125
Group II0.60.050.5591.66%0.8250.184-280.016
CoughGroup I0.60.20.466.66%0.5980.134-280.016
Group II1.50.351.173.33%0.7880.176-136<0.001
Sore ThroatGroup I0.650.150.576.92%0.6880.154-360.008
Group II0.500.5100%0.6060.135-450.004
TonsilsGroup I0.350.10.2571.42%0.4440.099-150.063
Group II0.70.50.228.57%0.4100.091-100.125
Pain AbdomenGroup I1.350.50.8562.96%0.5870.131-120<0.001
Group II0.50.150.3570%0.4890.109-280.016
VomitingGroup I0.5500.55100%0.6860.153-450.004
Group II0.350.050.385.71%0.4700.105-210.031
Loose StoolsGroup I0.50.050.4590%0.6040.135-360.008
Group II0.1500.15100%0.3660.081-60.250

Table 3: Therapy effect on subjective parameters depending upon their frequency (before and after treatment)

Signs and symptomsGroupsMeand% ReliefSD±SE±W valuep value
BTAT
FeverGroup I0.90.150.7583.33%0.640142-91<0.001
Group II0.70.150.5578.57%0.6860.153-450.004
Running NoseGroup I0.40.150.2562.5%0.4440.099-150.125
Group II0.550.10.4581.81%0.6860.153-280.016
CoughGroup I0.750.20.5573.33%0.760.169-360.008
Group II1.450.60.8558.62%0.5870.131-120<0.001
Sore ThroatGroup I0.70.150.5578.57%0.830.184-360.008
Group II0.70.250.4564.28%0.5100.114-450.004
TonsilsGroup I0.450.150.366.66%0.5710.127-150.063
Group II10.50.550%0.6880.153-360.008
Pain AbdomenGroup I1.40.60.857.14%0.5230.116-120<0.001
Group II0.70.350.3550%0.4890.109-280.016
VomitingGroup I0.500.5100%0.6060.136-450.004
Group II0.350.050.385.71%0.7590.169-210.031
Loose StoolsGroup I0.60.20.466.66%0.5980.133-280.016
Group II0.2500.25100%0.6380.142-60.250

Table 4: Inter-group comparison of subjective parameters

Morbidity FeaturesMean diff. (BT-AT)Diff. in % ReliefMann Whitney Rankp value
Group IGroup II
FeverSeverity0.80.7-7.5%4290.616
Frequency0.750.554.73%4460.336
Running
Nose
Severity0.250.55-20.24%3750.355
Frequency0.250.45-19.31%3850.506
CoughSeverity0.41.1-6.67%3130.009
Frequency0.550.8514.71%3540.136
Sore ThroatSeverity0.50.5-23.08%4050.903
Frequency0.550.4514.29%4090.989

TonsilsSeverity0.250.242.85%4200.796
Frequency0.30.516.66%3790.408
Pain AbdomenSeverity0.850.35-7.04%4970.019
Frequency0.80.357.14%4930.024
VomitingSeverity0.550.314.29%4460.335
Frequency0.50.314.29%4430.378
Loose StoolsSeverity0.450.15-10%4610.166
Frequency0.40.25-40%444.50.355

Table 5: Effect of therapy on objective criteria (Difference observed before and after treatment)

InvestigationGroupsMeand% changeSD±SE±‘t’ valuep value
BTAT
IgGGroup I10.6510.71-0.06-0.56%0.5210.116-0.5190.610
Group II9.79710.58-0.783-7.99%1.0060.224-3.4800.003

Table 6: Intergroup comparison of objective criteria

InvestigationMean diff (BT-AT)Diff. in % Relief‘t’valuep value
Group IGroup II
IgG-0.06-0.78313.05%2.8520.007

Table 7: Effect of therapy on laboratory parameters

InvestigationGroupsMeand% changeSD±SE±‘t’valuep value
BTAT
HbGroup I12.8413.135-0.295-2.2970.7870.176-1.6760.110
Group II12.46512.515-0.05-0.4011.022.240.2180.830
TLCGroup I6.3965.7880.6089.5051.9960.4461.3630.189
Group II7.7736.2641.5119.432.6050.5822.5930.018
NEUGroup I58.7654.254.517.67513.42.9961.5050.149
Group II62.28554.297.99512.849.7762.1863.6570.002
LYMGroup I33.4631.571.895.64813.5193.0230.6250.539
Group II31.3333.895-2.565-8.1878.2341.8411.3930.180
MIDGroup I5.1455.33-0.185-3.5951.7230.385-0.4800.637
Group II5.325.705-0.385-7.2361.970.441-0.8740.393
ESRGroup I11.18.352.7524.778.2451.8441.4920.415
Group II11.711.9-0.2-1.7098.0891.809-0.1110.913
SGOTGroup I25.927.4-1.5-5.7918.0431.798-0.8340.415
Group II34.228.16.117.8417.0723.8171.5980.127
SGPTGroup I18.922.35-3.45-18.2510.8652.43-1.4200.172
Group II25.220.654.5518.0620.7864.6480.9790.340

Table 8: Intergroup comparison of laboratory parameters

InvestigationsMean diff. (BT-AT)Diff. in % Relief‘t’valuep value
Group IGroup II
Hb-0.295-0.05-1.896%-0.8470.402
TLC0.6081.51-9.925%-1.2290.227
NEU4.517.995-5.165%-0.9400.353
LYM1.89-2.56513.84%1.2590.216
MID-0.185-0.3853.641%0.3420.734
ESR2.75-0.226.48%1.1420.261
SGOT-1.56.1-23.63%-1.8010.080
SGPT-3.454.55-36.31%-1.5250.135

Discussion

Subjective Parameters

Group I (Madhukadi Ghrita) showed a highly significant improvement in fever, abdominal pain (severity) and the frequency of fever and cough.

Significant improvements were also observed in the severity of cough, sore throat, vomiting and loose stools, as well as in the frequency of abdominal pain, sore throat and tonsillitis. However, the results were insignificant for the severity of running nose and tonsillitis, as well as the frequency of running nose and loose stools.


Group II (Samangadi Leha) showed a highly significant improvement in cough (both in severity and frequency). Other morbidity features showed significant results, while the changes in tonsils, loose stool severity, and frequency of a running nose were not statistically significant.

In the intergroup comparison, a statistically significant difference was observed in cough relief (severity) and pain abdomen (severity and frequency). Group II demonstrated superior results for cough relief, while Group I showed better outcomes for pain abdomen. Other subjective parameters in intergroup comparison showed insignificant result between the two Groups.

Objective Parameters

Group I showed minimal impact on IgG levels, whereas Group II exhibited a statistically significant increase, indicating stronger immunomodulatory effects. Intergroup analysis revealed a significant difference (p < 0.05), confirming the superior efficacy of Group II in enhancing IgG levels.

Group II showed a significant reduction in TLC and neutrophil levels, while changes in hemoglobin, lymphocytes, MID counts, ESR, and liver enzymes (SGOT, SGPT) were not statistically significant in either group. Intergroup comparison revealed no significant differences in any parameter, indicating a similar impact in both groups.

Probable mode of action of the trial drugs-

1. Madhukadi Ghrita

Table 9: Pharmacological actions

IngredientsKarmaAction based on pharmacological studies
MadhukaBalya, Vatapittajita, SwaryaAnti-tussive, Anti-inflammatory, Anti-microbial, Hepatoprotective, Immunomodulatory
VachaKanthya, Deepani, Vatahara, Kaphahara, AgnivardhakaAnti- inflammatory, Anti-bacterial, Broncho-dilation, Immunomodulatory, Neurologic effect
PippaliKaphavatashamaka, Deepana, Ruchya, Kasahara, Rasayana, BalyaAnti-microbial, effect on Respiratory System, Immunomodulatory, Anti-tumor, Hepatoprotective
ChitrakaDeepana, Pachana, Grahi, Kanthya, Jwaraghna, RasayanaAnti-inflammatory, Antimicrobial, Antioxidant,Nephroprotective, Hepatoprotective
HaritkiDeepana, Pachana, Anulomana, Grahi, Kaphaghna, Srotah-shodhana, RasayanaAnti- inflammatory, Anti-bacterial, Antidiarrheal, Immunomodulatory, Hepatoprotective
BibhitakiVedanasthapana, Deepana, Anulomana, Grahi, Chhardinigrahana, Kaphaghna, JwaraghnaAntipyretic, Antibacterial, Antidiarrheal, Analgesic, Immunomodulatory, Hepatoprotective
AmalakiBalya, Deepana, Anulomana, Stambhana, Kaphaghna, Jwaraghna, RasayanaAntipyretic, Analgesic, Anti-bacterial, Antioxidant,Immunomodulatory, Hepatoprotective
Go GhritaAgnideepana, Balya, Ojovardhaka, Rasayana, Ruchya, Vatapittaprashamna, Vayasthapana,Anti- inflammatory, effect on GIT, Anti-cancer, Antihyperlipidemic

Table 10: Therapeutic indication

SNTherapeutic IndicationDrug ingredientsImprovement in Clinical Features
1. JwaraghnaMadhuka, Chitraka, Haritaki, Bibhitaki, AmalakiFever
2. PratishyayaHaritaki, BibhitakiRunning Nose
3. KasaghnaMadhuka, Vacha, Pippali, Haritaki, Bibhitaki, AmalakiCough
4. DahashamakaMadhuka, AmalakiSore Throat
5. ShothharaPippali, Chitraka, Haritaki, Bibhitaki,Sore Throat
6. UdarashoolaPippali, Chitraka, Haritaki, AmalakiPain Abdomen
7. ChardighnaMadhuka, BibhitakiVomiting
8. AtisaraghnaMadhuka, BibhitakiLoose stools
9. Deepana-PachanaVacha, Pippali (Deepana), Chitraka, HaritakiFever, Pain Abdomen
10.RasayanaPippali, Chitraka, Haritaki, Amalaki, Go GhritaImmunomodulatory & strengthening
11.BalyaMadhuka, Pippali, Amalaki, Go GhritaImmunomodulatory & strengthening

2. Samangadi Leha

Table 11: Pharmacological actions

IngredientsKarmaAction based on pharmacological studies
SamangaShothahara, AtisaraghnaAnti-microbial, Anti-inflammatory & analgesic, Anti-diarrheal Immunomodulatory Hepatoprotective

HaritakiDeepana, Pachana, Anulomana, Grahi, Kaphaghna, Srotah-Shodhana, RasayanaAnti- inflammatory, Anti-bacterial, Antidiarrheal, Immunomodulatory, Hepatoprotective
BibhitakiVedanasthapana, Deepana, Anulomana, Grahi, Chhardinigrahana, Kaphaghna, JwaraghnaAntipyretic, Antibacterial, Antidiarrheal, Analgesic, Immunomodulatory, Hepatoprotective
AmalakiBalya, Deepana, Anulomana, Stambhana, Kaphaghna, Jwaraghna, RasayanaAntipyretic, Analgesic, Anti-bacterial, Antioxidant,Immunomodulatory, Hepatoprotective
BrahmiDeepana, Pachana, Vedanasthapana, ShothaharaAnti- inflammatory, Anti-Asthmatic, Immunostimulatory, Gastroprotective, Hepatoprotective
BalaRasayana, Kasahara, VedanaharaAnti- inflammatory Antibacterial, Analgesic, Immunomodulatory, Hepatoprotective
AtibalalaRasayana, Kasahara, VedanaharaAnalgesic, Antidiarrheal, Wound healing, Immunomodulatory, Hepatoprotective
ChitrakaDeepana, Pachana, Grahi, Kanthya, Jwaraghna, RasayanaAnti-inflammatory, Antimicrobial, Antioxidant,Nephroprotective, Hepatoprotective
MadhuAgni Deepaka, Balya, Lekhaniya, Shodhana, TridoshaprashamanaAnti-bacterial, Anti-oxidant property, source of Dietary fiber, Vit C, Vit.B6
Go GhritaAgnideepana, Balya, Ojovardhaka, Rasayana, Ruchya, Vatapittaprashamna, VayasthapanaAnti- inflammatory, effect on GIT, Anti-cancer, Antihyperlipidemic

Table 12: Therapeutic indication

SNTherapeutic IndicationDrug ingredientsImprovement in Clinical Features
1.JwaraghnaBrahmi, Chitraka, Haritaki, Bibhitaki, AmalakiFever
2.PratishyayaHaritaki, BibhitakiRunning Nose
3.KasaghnaHaritaki, Bibhitaki, Amalaki, Brahmi, Bala, AtibalaCough
4.DahashamakaAmalakiSore Throat
5.Shothhara /VedanaharaChitraka, Haritaki, Bibhitaki, Brahmi, Bala, AtibalaSore Throat
6.UdarashoolaChitraka, Haritaki, AmalakiPain Abdomen
7.ChardighnaBibhitakiVomiting
8.AtisaraghnaBibhitaki, Bala, AtibalaLoose stools
9.Deepana-PachanaHaritaki, Brahmi, ChitrakaFever, Pain Abdomen
10.RasayanaHaritaki, Amalaki, Bala, Atibala, Chitraka, Go GhritaImmunomodulatory & strengthening
11.BalyaMadhu, Amalaki, Go GhritaImmunomodulatory & strengthening

Madhukadi Ghrita predominantly exhibits Madhura Rasa, Sheeta Veerya, Snigdha and Guru Guna, and Madhura Vipaka, making it highly nourishing and Vata-Pitta Shamaka. Ingredients like Madhuka, Ghrita, and Amalaki contribute to its immune-strengthening and rejuvenating effects, while Pippali, Vacha, and Chitraka support digestion and metabolism through their Katu Rasa and Teekshana Guna.

Most of the drugs in Samangadi Leha shows a predominance of Kashaya, Tikta, and Madhura Rasa, along with Laghu, Ruksha, and Snigdha Guna, which support detoxification, digestion and nourishment. Its primarily Sheeta Veerya helps pacify Pitta and control inflammation, while Madhura Vipaka promotes Ojas and sustains immunity. The formulation is largely Tridosha Shamaka, with a specific emphasis on Kapha-Pitta pacification, thereby enhancing Vyadhikshamatva in children.

Conclusion

Children with weakened immunity are more prone to recurrent infections, particularly of the respiratory and gastrointestinal tracts, leading to compromised health and development.

The concept of Vyadhikshamatva in Ayurveda emphasizes strengthening the immune response through Balya and Rasayana interventions. Both formulations showed effectiveness in reducing the frequency and severity of recurrent RTIs and GIT disorders. Madhukadi Ghrita (Group I) was more effective in providing rapid symptomatic relief, Samangadi Leha (Group II) had statistically significant result in IgG level, indicating stronger immunomodulatory activity and better long-term immune support. The findings suggest that Samangadi Leha may be better drug of choice for more sustained enhancement of Vyadhikshamatva.

References

1. https://data. unicef. org/topic/child-srvival/under-five-mortality/. . [Crossref][PubMed][Google Scholar]

2. Abbas, A. K. , Lichtman, A. H. , & Pillai, S. (2017). Cellular and Molecular Immunology (9th ed.). Elsevier [Crossref][PubMed][Google Scholar]


3. Rohini Dharwal, Rakesh Sharma. Immune enhancing measures in Children. J Ayurveda Integr Med Sci [Internet]. 2024Jun. 15 [cited 2025Jun.13];9(4):150 -154 [Crossref][PubMed][Google Scholar]

4. Tripathi, Jyoti & Singh, Heisnam. (1999). The Concept and Practice of Immunomodulation in Ayurveda and the Role of Rasayanas as Immunomodulators. Ancient science of life. 19. 59-63 [Crossref][PubMed][Google Scholar]

5. Singh RH. Foundations of Immunology in Ayurvedic Classics. Indian Journal of History of Science, 50. 1 (2015) 83-94. [Crossref][PubMed][Google Scholar]

Disclaimer / Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of Journals and/or the editor(s). Journals and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.